|
1
|
El Maalouf G, Le Tourneau C, Batty GN,
Faivre S and Raymond E: Markers involved in resistance to
cytotoxics and targeted therapeutics in pancreatic cancer. Cancer
Treat Rev. 35:167–174. 2009. View Article : Google Scholar
|
|
2
|
Berlin JD, Catalano P, Thomas JP, Kugler
JW, Haller DG and Benson AB III: Phase III study of gemcitabine in
combination with fluorouracil versus gemcitabine alone in patients
with advanced pancreatic carcinoma: Eastern Cooperative Oncology
Group Trial E2297. J Clin Oncol. 20:3270–3275. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Heinemann V, Quietzsch D, Gieseler F,
Gonnermann M, Schönekäs H, Rost A, Neuhaus H, Haag C, Clemens M,
Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W,
Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A and
Wilkowski R: Randomized phase III trial of gemcitabine plus
cisplatin compared with gemcitabine alone in advanced pancreatic
cancer. J Clin Oncol. 24:3946–3952. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bernhard J, Dietrich D, Scheithauer W,
Gerber D, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schüller
J, Saletti P, Bauer J, Figer A, Pestalozzi BC, Köhne CH, Mingrone
W, Stemmer SM, Tàmas K, Kornek GV, Koeberle D and Herrmann R;
Central European Cooperative Oncology Group. Clinical benefit and
quality of life in patients with advanced pancreatic cancer
receiving gemcitabine plus capecitabine versus gemcitabine alone: a
randomized multicenter phase III clinical trial - SAKK
44/00-CECOG/PAN1.3.001. J Clin Oncol. 26:3695–3701. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Moore MJ, Goldstein D, Hamm J, Figer A,
Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos
D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M and
Parulekar W; National Cancer Institute of Canada Clinical Trials
Group. Erlotinib plus gemcitabine compared with gemcitabine alone
in patients with advanced pancreatic cancer: a phase III trial of
the National Cancer Institute of Canada Clinical Trials Group. J
Clin Oncol. 25:1960–1966. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Philip PA, Benedetti J, Corless CL, Wong
R, O’Reilly EM, Flynn PJ, Rowland KM, Atkins JN, Mirtsching BC,
Rivkin SE, Khorana AA, Goldman B, Fenoglio-Preiser CM, Abbruzzese
JL and Blanke CD: Phase III study comparing gemcitabine plus
cetuximab versus gemcitabine in patients with advanced pancreatic
adenocarcinoma: Southwest Oncology Group-directed intergroup trial
S0205. J Clin Oncol. 28:3605–3610. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kindler HL, Friberg G, Singh DA, Locker G,
Nattam S, Kozloff M, Taber DA, Karrison T, Dachman A, Stadler WM
and Vokes EE: Phase II trial of bevacizumab plus gemcitabine in
patients with advanced pancreatic cancer. J Clin Oncol.
23:8033–8040. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Storniolo AM, Enas NH, Brown CA, Voi M,
Rothenberg ML and Schilsky R: An investigational new drug treatment
program for patients with gemcitabine: results for over 3000
patients with pancreatic carcinoma. Cancer. 85:1261–1268. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang C, Yang A, Zhang B, Yin Q, Huang H,
Chen M and Xie J: PANC-1 pancreatic cancer cell growth inhibited by
cucurmosin alone and in combination with an epidermal growth factor
receptor-targeted drug. Pancreas. 43:291–297. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Niu BZ, Chen G, Li LJ, Wu YD and Zhao YP:
Drug resistance and activity changes of thioredoxin reductase in
pancreatic cancer cell strain SW1990 induced by gemcitabine.
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 27:606–610. 2005.(In Chinese).
PubMed/NCBI
|
|
11
|
Yao J, Feng FY, Lin C, Zhang XY, Fu M,
Liang X and Yang Y: The mechanism of resistance to
2′,2′-difluorodeoxycytidine (gemcitabine) in a pancreatic cancer
cell line. Zhonghua Zhong Liu Za Zhi. 27:721–726. 2005.(In
Chinese).
|
|
12
|
An Y, Yao J, Wei JS, Lu ZP, Cai HH, Dai
CC, Qian ZY, Xu ZK and Miao Y: Establish a gemcitabine-resistant
pancreatic cancer cell line SW1990/GZ and research the relationship
between SW1990/GZ and pancreatic cancer stem cell. Zhonghua Wai Ke
Za Zhi. 48:999–1003. 2010.(In Chinese). PubMed/NCBI
|
|
13
|
Togawa A, Ito H, Kimura F, Shimizu H,
Ohtsuka M, Shimamura F, Yoshidome H, Katoh A and Miyazaki M:
Establishment of gemcitabine-resistant human pancreatic cancer
cells and effect of brefeldin-a on the resistant cell line.
Pancreas. 27:220–224. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Kazuno H, Sakamoto K, Fujioka A, Fukushima
M, Matsuda A and Sasaki T: Possible antitumor activity of
1-(3-C-ethynyl-β-d-ribo-pentofuranosyl)cytosine (ECyd, TAS-106)
against an established gemcitabine (dFdCyd)-resistant human
pancreatic cancer cell line. Cancer Sci. 96:295–302. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kagawa S, Takano S, Yoshitomi H, Kimura F,
Satoh M, Shimizu H, Yoshidome H, Ohtsuka M, Kato A, Furukawa K,
Matsushita K, Nomura F and Miyazaki M: Akt/mTOR signaling pathway
is crucial for gemcitabine resistance induced by Annexin II in
pancreatic cancer cells. J Surg Res. 178:758–767. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Uchiyama-Kokubu N and Watanabe T:
Establishment and characterization of adriamycin-resistant human
colorectal adenocarcinoma HCT-15 cell lines with multidrug
resistance. Anticancer Drugs. 12:769–779. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Goan YG, Zhou B, Hu E, Mi S and Yen Y:
Overexpression of ribonucleotide reductase as a mechanism of
resistance to 2,2-difluorodeoxycytidine in the human KB cancer cell
line. Cancer Res. 59:4204–4207. 1999.PubMed/NCBI
|
|
18
|
Nakano Y, Tanno S, Koizumi K, Nishikawa T,
Nakamura K, Minoguchi M, Izawa T, Mizukami Y, Okumura T and Kohgo
Y: Gemcitabine chemoresistance and molecular markers associated
with gemcitabine transport and metabolism in human pancreatic
cancer cells. Br J Cancer. 96:457–463. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
García-Manteiga J, Molina-Arcas M, Casado
FJ, Mazo A and Pastor-Anglada M: Nucleoside transporter profiles in
human pancreatic cancer cells: role of hCNT1 in
2′,2′-difluorodeoxy-cytidine-induced cytotoxicity. Clin Cancer Res.
9:5000–5008. 2003.
|
|
20
|
Bergman AM, Pinedo HM and Peters GJ:
Determinants of resistance to 2′,2′-difluorodeoxycytidine
(gemcitabine). Drug Resist Updat. 5:19–33. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kroep JR, Loves WJ, van der Wilt CL,
Alvarez E, Talianidis I, Boven E, Braakhuis BJ, van Groeningen CJ,
Pinedo HM and Peters GJ: Pretreatment deoxycytidine kinase levels
predict in vivo gemcitabine sensitivity. Mol Cancer Ther.
1:371–376. 2002.PubMed/NCBI
|
|
22
|
Graber HU, Friess H, Zimmermann A, Korc M,
Adler G, Schmid R and Büchler MW: Bak expression and cell death
occur in peritumorous tissue but not in pancreatic cancer cells. J
Gastrointest Surg. 3:74–80. 1999. View Article : Google Scholar : PubMed/NCBI
|
